Acadia Pharmaceuticals
ACAD · Nasdaq · United States
Share price · ACAD
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ACAD's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026+10.8%
- 9 Nov 2026-22.3%
- 25 Sep 2026-6.8%
- 24 Sep 2026-12.8%
- 21 Sep 2026-3.3%
Nothing announced by ACAD that day or the session before.
- 18 Aug 2026+4.0%
Nothing announced by ACAD that day or the session before.
- 5 Aug 2026+6.1%
- 26 Jun 2026+6.7%
Nothing announced by ACAD that day or the session before.
- 7 May 2026+5.0%
- 2 Mar 2026-7.1%
Nothing announced by ACAD that day or the session before.
Share of unusual movement by asset
For each asset, the share of ACAD's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
Pimavanserin(Nuplazid) | Approved | 5-HT2A/2C receptor · Serotonin 5-HT2A receptor (antagonist / inverse agonist)Small molecule | Parkinson's Disease Psychosis |
| Approved | —Peptide | Rett Syndrome | |
| Phase 3 | Serotonin 5-HT2A receptor (antagonist / inverse agonist)Small molecule | Alzheimer's DiseaseAlzheimer's Disease Psychosis | |
| Phase 2 | NMDA receptorSmall molecule | Major Depressive Disorder |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
2028 (2)
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (19)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $342M | $76M | $322M+ $654M short-term inv. | —$12M operating cash flow | report ↗ |
View 18 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $308M | $82M | $385M+ $571M short-term inv. | —$101M operating cash flow | report ↗ |
| 2026-Q1 | $268M | $77M | $282M+ $569M short-term inv. | —$34M operating cash flow | report ↗ |
| 2025-Q3 | $279M | $88M | $258M+ $589M short-term inv. | —$74M operating cash flow | report ↗ |
| 2025-Q2 | $265M | $78M | $254M+ $508M short-term inv. | —$64M operating cash flow | report ↗ |
| 2025-Q1 | $244M | $78M | $218M+ $464M short-term inv. | —$20M operating cash flow | report ↗ |
| 2024-Q3 | $250M | $67M | $155M+ $410M short-term inv. | —$63M operating cash flow | report ↗ |
| 2024-Q2 | $242M | $76M | $177M+ $324M short-term inv. | —$25M operating cash flow | report ↗ |
| 2024-Q1 | $206M | $60M | $205M+ $266M short-term inv. | —$29M operating cash flow | report ↗ |
| 2023-Q4 | — | — | $189M+ $250M short-term inv. | —$85M operating cash flow | report ↗ |
| 2023-Q3 | $212M | $157M | $98M+ $248M short-term inv. | $65M-$59M operating cash flow | report ↗ |
| 2023-Q2 | $165M | $59M | $108M+ $267M short-term inv. | —$8.2M operating cash flow | report ↗ |
| 2023-Q1 | $118M | $69M | $291M+ $112M short-term inv. | $43M-$18M operating cash flow | report ↗ |
| 2022-Q4 | — | — | $115M+ $302M short-term inv. | $42M-$24M operating cash flow | report ↗ |
| 2022-Q3 | $131M | $81M | $155M+ $282M short-term inv. | $27M-$0.7M operating cash flow | report ↗ |
| 2022-Q2 | $135M | $76M | $140M+ $297M short-term inv. | $34M-$13M operating cash flow | report ↗ |
| 2022-Q1 | $115M | $129M | $205M+ $241M short-term inv. | $113M-$76M operating cash flow | report ↗ |
| 2021-Q4 | — | — | $147M+ $373M short-term inv. | $43M-$23M operating cash flow | report ↗ |
| 2021-Q3 | $132M | $59M | $95M+ $446M short-term inv. | $14M-$17M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $1.1B | $329M | $178M+ $642M short-term inv. | —$110M operating cash flow | report ↗ |
Acadia Pharmaceuticals reported full-year 2025 revenue of $1,071.51M, up 11.9% YoY, with research and development spend of $328.8M, up 8.4% YoY. Cash and equivalents stood at $177.7M, and the company recorded net income of $391M. The company also reported non-GAAP adjusted total revenues of $1.08B for the year, up 14% YoY, reflecting an adjustment for a one-time Inflation Reduction Act rebate accrual charge.
For 2026, Acadia guided total revenues of $1.22 to $1.28B, NUPLAZID net sales of $760 to $790M, DAYBUE net sales of $460 to $490M, R&D expense of $385 to $410M, and SG&A expense of $660 to $700M. The company expects top-line results from the remlifanserin Phase 2 RADIANT study in Alzheimer’s disease psychosis between August and October 2026, and has shipped initial DAYBUE STIX product to patients ahead of a broader launch planned for early Q2 2026. Acadia also completed a planned 30% expansion of its NUPLAZID customer-facing teams.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $958M | $303M | $320M+ $436M short-term inv. | —$158M operating cash flow | report ↗ |
| 2023-FY | $726M | $352M | $189M+ $250M short-term inv. | $15M$17M operating cash flow | report ↗ |
| 2022-FY | $517M | $362M | $115M+ $302M short-term inv. | $54M-$114M operating cash flow | report ↗ |
| 2021-FY | $484M | $239M | $147M+ $373M short-term inv. | $42M-$126M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 22 sales ($2.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-30 | Schneyer Mark C. · EVP, CHIEF FINANCIAL OFFICER | Open-market sale | 3,321 | $20.88 | $69K | Form 4 |
| 2026-10-15 | Schneyer Mark C. · EVP, CHIEF FINANCIAL OFFICER | Award / grant | 6,815 | — | — | Form 4 |
| 2026-08-06 | Schneyer Mark C. · EVP, CHIEF FINANCIAL OFFICER | Option exercise | 14,292 | $17.84 | $255K | Form 4 |
| 2026-08-06 | Schneyer Mark C. · EVP, CHIEF FINANCIAL OFFICER | Open-market sale | 5,000 | $29.00 | $145K | Form 4 |
| 2026-08-06 | Schneyer Mark C. · EVP, CHIEF FINANCIAL OFFICER | Open-market sale | 9,292 | $29.34 | $273K | Form 4 |
| 2026-08-06 | Schneyer Mark C. · EVP, CHIEF FINANCIAL OFFICER | Option exercise (derivative) | 14,292 | — | — | Form 4 |
| 2026-08-05 | Schneyer Mark C. · EVP, CHIEF FINANCIAL OFFICER | Option exercise | 5,849 | $17.84 | $104K | Form 4 |
| 2026-08-05 | Schneyer Mark C. · EVP, CHIEF FINANCIAL OFFICER | Open-market sale | 5,849 | $29.00 | $170K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 338 reporting institutions held 165.0M shares ($3.6B, 95.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 42,896,690 | $954.9M |
| 2 | BlackRock, Inc. | 21,550,921 | $479.7M |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 8,671,645 | $193.0M |
| 4 | STATE STREET CORP | 8,332,771 | $185.5M |
| 5 | RTW INVESTMENTS, LP | 7,144,524 | $159.0M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 5,661,400 | $126.0M |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 3,464,689 | $77.1M |
| 8 | FIRST TRUST ADVISORS LP | 3,343,868 | $74.4M |
| 9 | DIMENSIONAL FUND ADVISORS LP | 3,155,160 | $70.2M |
| 10 | Palo Alto Investors LP | 2,872,695 | $63.9M |
| 11 | Point72 Asset Management, L.P. | 2,577,916 | $57.4M |
| 12 | BRAIDWELL LP | 2,471,199 | $55.0M |
| 13 | Pictet Asset Management Holding SA | 2,026,044 | $44.7M |
| 14 | RENAISSANCE TECHNOLOGIES LLC | 1,724,196 | $38.4M |
| 15 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1,569,491 | $34.9M |